Eisai R&D Day Highlights Diverse Pipeline Fueled By Large, Small Molecules
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Japanese pharma company Eisai aims to file its toll-like receptor 4 antagonist eritoran NDA for the treatment of severe sepsis simultaneously in U.S., Europe and Japan in fiscal year 2009, the company announced July 17 at its R&D Day in Tokyo